Director of the Department of Urology, Peking University Third Hospital; Deputy Secretary of the Party Branch Deputy Director of the Beijing Key Laboratory of Medical-Engineering Interdisciplinary and Translational Research for Malignant Tumors Chief Physician, Professor, Doctoral Supervisor, Postdoctoral Co-Supervisor Specializes in robot-assisted laparoscopic surgery for complex and difficult tumors, with over 100 invited surgical demonstrations at major academic conferences in Germany and China. Professional Experience Clinical Master's Degree, Peking University Health Science Center; Clinical Doctorate, Peking University Health Science Center; Postdoctoral Fellow, Medical University of Vienna; Clinical Fellow, Queen Mary Hospital, University of Hong Kong; Visiting Scholar at internationally renowned institutions including Mayo Clinic, Cleveland Clinic, Johns Hopkins University, MD Anderson Cancer Center, University of California, San Francisco (UCSF), Keck School of Medicine of the University of Southern California (USC), Guy's Hospital (UK), Royal Marsden Hospital (UK), Oxford University Hospitals (UK), and Fundació Puigvert (Spain). 2004.8-2006.7: Chief Resident, Department of Urology, Peking University Third Hospital 2006.8-2011.7: Attending Physician, Department of Urology, Peking University Third Hospital 2011.8-2016.8: Associate Chief Physician, Department of Urology, Peking University Third Hospital 2016.9-Present: Chief Physician, Department of Urology, Peking University Third Hospital 2022.10-Present: Director, Department of Urology, Peking University Third Hospital Research Activities Principal Investigator of 3 projects funded by the National Natural Science Foundation of China (General Program), 6 provincial and ministerial projects including the Beijing Natural Science Foundation, and over 20 other research projects. Published over 100 papers as first author or corresponding author in journals including Nature Cancer, Advanced Materials, and Cell & Bioscience, with the highest single-paper impact factor reaching 32.086. Lead writer and co-editor of over 10 guidelines and consensus statements from CUA, CSCO, and CACA; chief editor, chief translator, and contributor to over 10 monographs and textbooks. Awards and Honors Received 5 scientific and technological achievement awards as the primary contributor, including the Second Prize of the Beijing Science and Technology Progress Award, the First Huaxia Young Medical Science and Technology Award, and the Third Prize of the Huaxia Medical Science and Technology Award. Recipient of the WCUS "Rising Star Award," the 9th Beijing Outstanding Physician Award, the Capital Medical "Excellent Promotion Plan," the Special Contribution Award for Chinese Urological Tumor Minimally Invasive Surgery, the First Young and Middle-Aged Tumor Prevention and Treatment Elite Award, the Peking University Health Science Center Young Post Expert Award, and the PUTH Outstanding Talent Award. Publications Published over 100 papers as first author or corresponding author in journals including Nature Cancer, Advanced Materials, and Cell & Bioscience, with the highest single-paper impact factor reaching 32.086. Representative Publications: [1] Frosted slides decorated with silica nanowires for detecting circulating tumor cells from prostate cancer patients. ACS Appl Mater Interfaces. 2018, 10(23): 19545-19553. [2] Bioinspired superwettable microspine chips with directional droplet transportation for biosensing. ACS Nano. 2020,4(4):4654-4661. [3] Superwettable microchips with improved spot homogeneity toward sensitive biosensing. Biosens Bioelectron.2018,102:418-424. [4] Antibody-modified reduced graphene oxide film for circulating tumor cell detection in early-stage prostate cancer patients. RSC Adv.2019,9(17):9379-9385. [5] Candle soot-templated silica nanobiointerface chip for detecting circulating tumor cells from patients with urologic malignancies. RSC Adv.2018, 8(60):34566-34572. [6] Genomic alterations of renal cell carcinoma and clinical implications in the chinese population. Med Sci Monit. 2019, 25:2959-2965. [7] KLF2 inhibits the migration and invasion of prostate cancer cells by downregulating MMP2. Am J Mens Health. 2019,13(1): 1557988318816907. [8] Knotless retroperitoneoscopic nephron-sparing surgery for small renal masses: Comparison of bipolar sutureless technique and barbed suture technique. J Int Med Res. 2018,46(4):1649-1656. [9] Clinical significance of circulating tumor cells detection in renal cell carcinoma with thrombus :A STROBE-compliant study. Medicine (Baltimore).2020,99(22):e20615. [10] How to Prevent Bubbles in Microfluidic Channels. Langmuir. 2021,37(6): 2187-2194. Books and Translations Lead writer and co-editor of over 10 guidelines and consensus statements from CUA, CSCO, and CACA; chief editor, chief translator, and contributor to over 10 monographs and textbooks.